Press release
Metastatic Hepatocellular Carcinoma Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
DelveInsight's, "Metastatic Hepatocellular Carcinoma Pipeline Insight, 2025" report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in Metastatic Hepatocellular Carcinoma pipeline landscape. It covers the Metastatic Hepatocellular Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Metastatic Hepatocellular Carcinoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.Explore our latest breakthroughs in Metastatic Hepatocellular Carcinoma research. Learn more about our innovative pipeline today! @ Metastatic Hepatocellular Carcinoma Pipeline Outlook [https://www.delveinsight.com/sample-request/metastatic-hepatocellular-carcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Metastatic Hepatocellular Carcinoma Pipeline Report
* In July 2025, Sanofi announced a study is a phase 2 non-randomized, open-label, multi-cohort, multi-center study assessing the clinical benefit of SAR444245 (THOR-707) combined with other anticancer therapies for the treatment of participants aged 18 years and older with advanced and metastatic gastrointestinal cancer. This study is structured as a master protocol for the investigation of SAR444245 with other anticancer therapies.
* In June 2025, Merck Sharp & Dohme LLC conducted a study is to evaluate the efficacy and safety of lenvatinib and pembrolizumab in combination with TACE versus TACE plus oral and intravenous (IV) placebos in participants with incurable, non-metastatic hepatocellular carcinoma (HCC). The primary hypotheses are that pembrolizumab plus lenvatinib in combination with TACE is superior to placebo plus TACE with respect to progression-free survival (PFS) and overall survival (OS).
* DelveInsight's Metastatic Hepatocellular Carcinoma pipeline report depicts a robust space with 20+ active players working to develop 25+ pipeline therapies for Metastatic Hepatocellular Carcinoma treatment.
* The leading Metastatic Hepatocellular Carcinoma Companies such as Ionis Pharmaceuticals, CStone Pharmaceuticals, Coherus BioSciences, Tvardi Therapeutics, Sapience Therapeutics, Inc., Eureka Therapeutics Inc., Krystal Biotech, Inc., Replimune Inc., Beijing Syngentech Co., Ltd., Boehringer Ingelheim, AbbVie, Chugai Pharmaceutical, GenVivo, Inc., Suzhou Kintor Pharmaceutical Inc., Shanghai Henlius Biotech and others.
* Promising Metastatic Hepatocellular Carcinoma Pipeline Therapies such as Huaier Granule, Lenvatinib, Tislelizumab, GC33, Atezolizumab, Bevacizumab, Tiragolumab, Relatlimab, Nivolumab, Bevacizumab , and others.
Stay informed about the cutting-edge advancements in Metastatic Hepatocellular Carcinoma treatments. Download for updates and be a part of the revolution in cancer care @ Metastatic Hepatocellular Carcinoma Clinical Trials Assessment [https://www.delveinsight.com/sample-request/metastatic-hepatocellular-carcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Metastatic Hepatocellular Carcinoma Emerging Drugs Profile
* CS1003: CStone Pharmaceuticals
CS1003 or Nofazinlimab is a humanized recombinant IgG4 monoclonal antibody targeting human programmed cell death protein 1 (PD-1) being developed in solid tumors. Nofazinlimab shows comparable high binding affinities to the PD-1 of humans, cynomolgus monkey, and mouse, and can block the interaction of PD-1 with its ligands PD-L1 and PD-L2. The U.S. FDA has granted nofazinlimab Orphan Drug Designation (ODD) in July 2020 for the treatment of patients with HCC. CStone formed a strategic collaboration agreement with EQRx, under which EQRx licensed the exclusive rights to two immuno-oncology assets, sugemalimab and nofazinlimab, for development and commercialization outside of Greater China. CStone retains rights to nofazinlimab in Greater China, where it can continue to pursue development as a monotherapy or as part of its combination strategy for this drug. Currently, the drug is in Phase III stage of its development for the treatment of hepatocellular carcinoma.
* Casdozokitug: Coherus BioSciences
Casdozokitug is a human anti-IL-27 antibody designed to inhibit the activity of this immune regulatory cytokine. The company is focused on developing casdozokitug in particular tumor types where IL-27 secreted from macrophages appears to play an important role in the immunosuppressive tumor microenvironment and may contribute to resistance to treatment with immune checkpoint inhibitors. Preclinical studies have shown that treatment with casdozokitug blocks the immunosuppressive biologic effects of IL-27, resulting in immune cell activation in combination with other cancer therapies including anti-PD-1 therapy, as well as anti-tumor effects. Casdozokitug has been granted Orphan Drug designation and Fast Track designation for the treatment of refractory hepatocellular carcinoma from the FDA. It is the first IL-27 antibody to enter the clinic. Currently, the drug is in Phase II stage of its development for the treatment of hepatocellular carcinoma.
* TTI-101: Tvardi Therapeutics
TTI-101 is an orally bioavailable, small-molecule inhibitor of signal transducer and activator of transcription 3 (STAT3), a transcription factor whose upregulation and activation governs many hallmarks of cancer, inflammation, and fibrosis. Preclinically, TTI-101 has demonstrated an excellent pharmacokinetic profile, potency in inhibiting STAT3 activation, and efficacy in inhibiting tumor growth in xenograft and syngeneic tumor models. In its first-in-man Phase 1 trial conducted in patients with relapsed/refractory tumors, TTI-101 monotherapy was well-tolerated and had clinical activity across a broad range of tumors including multiple durable radiographic objective responses. Currently, the drug is in Phase I/II stage of its development for the treatment of hepatocellular carcinoma.
* ST316: Sapience Therapeutics, Inc.
ST316, a first-in-class antagonist of the interaction between -catenin and its co-activator BCL9, is being evaluated in the Phase I portion of a Phase I-II clinical study in patients with selected advanced unresectable and metastatic solid tumors. ST316-101 is an open-label, two-part study. The Phase I dose-escalation portion of the study is designed to determine the safety, tolerability, PK, and PD of ST316 in patients with selected advanced solid tumors likely to harbor abnormalities of the Wnt/-catenin signaling pathway. The Phase II dose-expansion portion aims to continue to assess the safety of ST316 as well as proof of concept in four specific tumor types known to harbor abnormalities of the Wnt/-catenin signaling pathway. Currently, the drug is in Phase I/II stage of its development for the treatment of hepatocellular carcinoma.
The Metastatic Hepatocellular Carcinoma Pipeline report provides insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Metastatic Hepatocellular Carcinoma with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Metastatic Hepatocellular Carcinoma Treatment.
* Metastatic Hepatocellular Carcinoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Metastatic Hepatocellular Carcinoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Metastatic Hepatocellular Carcinoma market.
Learn more about Metastatic Hepatocellular Carcinoma Drugs opportunities in our groundbreaking Metastatic Hepatocellular Carcinoma research and development projects @ Metastatic Hepatocellular Carcinoma Unmet Needs [https://www.delveinsight.com/sample-request/metastatic-hepatocellular-carcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Metastatic Hepatocellular Carcinoma Companies
Ionis Pharmaceuticals, CStone Pharmaceuticals, Coherus BioSciences, Tvardi Therapeutics, Sapience Therapeutics, Inc., Eureka Therapeutics Inc., Krystal Biotech, Inc., Replimune Inc., Beijing Syngentech Co., Ltd., Boehringer Ingelheim, AbbVie, Chugai Pharmaceutical, GenVivo, Inc., Suzhou Kintor Pharmaceutical Inc., Shanghai Henlius Biotech and others.
Metastatic Hepatocellular Carcinoma Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical
Metastatic Hepatocellular Carcinoma Products have been categorized under various Molecule types such as
* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy
Discover the latest advancements in Metastatic Hepatocellular Carcinoma treatment by visiting our website. Stay informed about how we're transforming the future of oncology @ Metastatic Hepatocellular Carcinoma Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/metastatic-hepatocellular-carcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Metastatic Hepatocellular Carcinoma Pipeline Report
* Coverage- Global
* Metastatic Hepatocellular Carcinoma Companies- Ionis Pharmaceuticals, CStone Pharmaceuticals, Coherus BioSciences, Tvardi Therapeutics, Sapience Therapeutics, Inc., Eureka Therapeutics Inc., Krystal Biotech, Inc., Replimune Inc., Beijing Syngentech Co., Ltd., Boehringer Ingelheim, AbbVie, Chugai Pharmaceutical, GenVivo, Inc., Suzhou Kintor Pharmaceutical Inc., Shanghai Henlius Biotech and others.
* Metastatic Hepatocellular Carcinoma Pipeline Therapies- Huaier Granule, Lenvatinib, Tislelizumab, GC33, Atezolizumab, Bevacizumab, Tiragolumab, Relatlimab, Nivolumab, Bevacizumab , and others.
* Metastatic Hepatocellular Carcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Metastatic Hepatocellular Carcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of Metastatic Hepatocellular Carcinoma Pipeline on our website @ Metastatic Hepatocellular Carcinoma Emerging Drugs and Companies [https://www.delveinsight.com/sample-request/metastatic-hepatocellular-carcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Metastatic Hepatocellular Carcinoma: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Metastatic Hepatocellular Carcinoma- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* CS1003: CStone Pharmaceuticals
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Casdozokitug: Coherus BioSciences
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I/II)
* ST316: Sapience Therapeutics, Inc.
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Inactive Products
* Metastatic Hepatocellular Carcinoma Key Companies
* Metastatic Hepatocellular Carcinoma Key Products
* Metastatic Hepatocellular Carcinoma- Unmet Needs
* Metastatic Hepatocellular Carcinoma- Market Drivers and Barriers
* Metastatic Hepatocellular Carcinoma- Future Perspectives and Conclusion
* Metastatic Hepatocellular Carcinoma Analyst Views
* Metastatic Hepatocellular Carcinoma Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=metastatic-hepatocellular-carcinoma-pipeline-appears-robust-with-20-key-pharma-companies-actively-working-in-the-therapeutics-segment-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/metastatic-hepatocellular-carcinoma-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Metastatic Hepatocellular Carcinoma Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight here
News-ID: 4096644 • Views: …
More Releases from ABNewswire

Occasions by Cindy Celebrates Five Decades of Excellence as Sugar Land's Premier …
Occasions by Cindy celebrates 54+ years of family-owned floral excellence in Sugar Land, boasting Premier Florist status, a comprehensive delivery network, and a continued commitment to artistic quality and customer satisfaction throughout the Greater Houston area.
Sugar Land's floral industry is in for a significant celebration with the announcement of expanded service capabilities by Occasions by Cindy [https://www.google.com/maps/place/Occasions+by+Cindy/@29.591314,-95.63456,17z/data=!3m1!4b1!4m6!3m5!1s0x8640e655eafdd13d:0xee06ddaed9f2bd9e!8m2!3d29.591314!4d-95.63456!16s%2Fg%2F11bvvxh5_w!5m1!1e3?entry=ttu&g_ep=EgoyMDI1MDcyMy4wIKXMDSoASAFQAw%3D%3D], marking over five decades of exceptional florist expertise throughout the Greater Houston metropolitan…

JudyMaids Introduces Advanced Team Certification Program for House Cleaning Serv …
JudyMaids expands professional cleaning services throughout Rockville with advanced team certification, specialized cleaning solutions, and community-focused service delivery that addresses diverse residential and commercial cleaning requirements.
Rockville's cleaning industry is experiencing significant enhancements with JudyMaids' announcement of an advanced team certification program and expanded service capabilities throughout the Maryland metropolitan area. The established cleaning company continues to strengthen its position as the region's trusted cleaning specialist through professional development initiatives and…

Cheapest 2025 Kansas City Chiefs Football Tickets Online: Use Promo Code CITY10 …
Find the cheapest 2025 Kansas City Chiefs ticket deals at CapitalCityTickets.com. Use promo code CITY10 to save extra on all seating options for both home and away games. Whether you want premium seats or budget-friendly options, CapitalCityTickets.com has you covered. Don't miss out on NFL action-secure your tickets early, save big, and cheer on the Chiefs live all season long!
Gear up for an electrifying 2025 NFL season with the Kansas…

PMHScribe Unveils AI-Charting Technology for Psychiatry in Partnership wIth Fast …
Cutting-edge scribe technology decreases the time medical practitioners spend charting.
Winston-Salem - July 26th, 2025 - PMHScribe recently launched an automated note-taking and charting software in partnership with FastTrack CEO to streamline psychiatric documentation for practitioners and patients. PMHScribe is rapidly increasing in customer count as it expands its platform.
PMHScribe captures audio during clinical sessions and converts it into fully formatted chart notes using methods that ensure the patient's safety and…
More Releases for Metastatic
Emerging Trends Influencing The Growth Of The Metastatic Urothelial Carcinoma Ma …
We've updated all our reports with current data on tariff changes, trade developments, and supply chain shifts affecting key industries.
How Big Is the Metastatic Urothelial Carcinoma Market Size Expected to Be by 2034?
The market size for metastatic urothelial carcinoma has seen exponential growth recently. The market will expand from a worth of $1.18 billion in 2024 to $1.42 billion in 2025, with a compound annual growth rate (CAGR) of 20.2%.…
Key Influencer in the Metastatic Cancer Drugs Market 2025: Surging Prevalence Of …
How Are the key drivers contributing to the expansion of the metastatic cancer drugs market?
The escalation in the incidence of metastatic cancers will be a driving force for the expansion of the metastatic cancer drugs market. Metastatic cancer is a late-stage cancer that spreads across the body. As the number of metastatic cancer cases escalates, so does the creation of innovative drugs to treat various kinds of metastatic cancers. The…
Major Force in the Metastatic Bone Disease Market 2025: Impact Of Bone Cancer Pr …
How Will the Metastatic Bone Disease Market Grow, and What Is the Projected Market Size?
The market size for metastatic bone disease has seen considerable growth in recent years. There is an expected increase from $17.14 billion in 2024 to $18.88 billion in 2025, with a compound annual growth rate (CAGR) of 10.1%. The substantial growth during the historical period can be credited to factors like rising aging population, heightened cancer…
Metastatic Melanoma Pipeline Therapeutics Assessment Report 2024 (Updated)
DelveInsight's, "Metastatic Melanoma Pipeline Insight 2024" report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in Metastatic Melanoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Metastatic Melanoma research. Learn more…
Combination Therapy Strategies for Metastatic Cancer
Metastatic cancer, where cancer cells spread from the primary tumor to distant organs, presents significant treatment challenges. Combination therapy strategies have emerged as a powerful approach to enhance treatment efficacy, overcome resistance, and improve patient outcomes in metastatic cancer.
Download Report:
https://www.kuickresearch.com/report-cancer-antibody-combinations-therapy-cancer-antibody-combination-monoclonal-antibodies-combination-drug-conjugate-antibodies-combination
One of the primary goals of combination therapy in metastatic cancer is to target both the primary tumor and metastatic sites. This comprehensive approach can improve overall disease control…
Metastatic Melanoma Pipeline Outlook Report 2024 (Updated)
DelveInsight's, "Metastatic Melanoma Pipeline Insight 2024" report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in the Metastatic Melanoma pipeline landscape. It covers the Metastatic Melanoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Metastatic Melanoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the…